Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
Conditions:  Fallopian Tube Carcinosarcoma;  Fallopian Tube Clear Cell Adenocarcinoma;  Fallopian Tube Transitional Cell Carcinoma;  Fallopian Tube Undifferentiated Carcinoma;  Germline BRCA1 Gene Mutation;  Germline BRCA2 Gene Mutation;  High Grade Fallopian Tube Serous A denocarcinoma;  High Grade Ovarian Serous Adenocarcinoma;  Ovarian Clear Cell Tumor;  Ovarian Seromucinous Carcinoma;  Ovarian Undifferentiated Carcinoma;  Platinum-Sensitive Fallopian Tube Carcinoma;  Platinum-Sensitive Ovarian Carcinoma;  Platinum-Sensitive Primary Peritoneal Carcinoma;  Primary Peritoneal Carcinosarcoma;  Primary Peritoneal Clear Cell Carcinoma;  Primary Peritoneal High Grade Serous Adenocarcinoma;  Primary Peritoneal Transitional Cell Carcinoma;  Primary Peritoneal Undifferentiated Carcinoma;  Recurrent Fallopian Tube Carcinoma;  Recurrent Ovarian Endometrioid Adenocarcinoma;  Recurrent Ovarian Serous Adenocarcinoma;  Recurrent Ovarian Transitional Cell Carcinoma;  Recurrent Primary Peritoneal Carcinoma Interventions:  Drug: Olaparib;  Biological: Tremelimumab Sponsor:  National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Carcinosarcoma | Fallopian Tube Cancer | Immunotherapy | Ovarian Cancer | Ovaries | Peritoneal Cancer | Research | Serous Carcinoma